You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Cost recovery impact statement: Blood, blood components and biologicals (human cell and tissue therapies), 1 July 2014 - 30 June 2015
Version 1.0, June 2014
3. Stakeholder engagement
The TGA external communication and education framework: Priorities and projects 2013-2015 describes the TGA's approach to providing:
- better information that is easily understood by consumers
- therapeutic goods information that can be received and shared by health professionals
- information that will provide greater certainty on regulatory arrangements for the therapeutic goods industry
It also details specific communication and education projects that will target consumers, health professionals or industry.
TGA consults with industry associations separately on regulatory matters and cost impacts relating to specific sectors. Industry associations are also consulted in the process of regulatory development and reform, and feedback is taken into account in developing regulatory implementation statements, and in developing cost recovery arrangements. Meetings are held with key industry representative bodies each year to discuss financial forecasts and as a part of the consultation process on cost recovery. The TGA also reports to stakeholders against a set of agreed Key Performance Indicators (KPIs).